MPM Oncology Impact Management »

Moonlake Immunot shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Moonlake Immunot (MLTX) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Moonlake Immunot

Tip: Access up to 7 years of quarterly data

All positions including Moonlake Immunot held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Moonlake Immunot by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $15M 343k 43.97
2024-03-31 $15M 296k 50.23
2023-09-30 $17M 294k 57.00
2023-06-30 $15M 295k 51.00

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Moonlake Immunot

BVF
Cormorant Asset Management
T. Rowe Price Associates
Citadel Advisors
Holocene Advisors
Goldman Sachs Group
Westfield Capital Management Company
Marshall Wace
Federated Investors
Alliancebernstein
Paradigm Biocapital Advisors
Logos Global Management
Fred Alger Management
Balyasny Asset Management
Nuveen Asset Management

View all funds holding Moonlake Immunot